OK-432 therapy for lymphangioma in children: Why and how does it work?

https://doi.org/10.1016/S0022-3468(96)90478-9Get rights and content

Abstract

Intralesional injection of OK-432 (lyophilized incubation mixture of group AStreptococcus pyogenes of human origin) is safe and effective therapy for lymphangioma. The authors evaluated the mechanism of this therapy in 6 patients who had cystic lymphangioma. The intracystic fluid of the cystic lymphangioma was aspirated before and after (on days 1 and 4) the OK-432 therapy. Changes in cell populations and cytokine productions in each aspirated fluid were analyzed. White blood cells in the intracystic fluid increased markedly in number. Before OK-432 therapy, 96% of the intracystic white blood cells were lymphocytes, and the remaining were neutrophils and macrophages. On day 1, the percentages of neutrophils and macrophages increased to 72% and 21%, respectively. On day 4, the percentage of lymphocytes increased to 72%. Flow cytometry analysis using monoclonal antibodies showed that the number of natural killer cells (CD56+) and T cells (CD3+) had increased. The activity of cytotoxic tumor necrosis factor (TNF) and interleukin-6 increased immediately after OK-432 injection and remained high in titer until day 4. These findings suggest that the white blood cells induced and activated by OK-432, and the cytokines (including TNF) produced by these cells increased the endothelial permeability, and thus the accelerated lymph drainage and increased lymph flow led to shrinkage of the cystic spaces.

Reference (19)

  • OgitaS et al.

    OK-432 therapy for unresectable lymphangioma in children

    J Pediatr Surg

    (1991)
  • OgitaS et al.

    OK-432 therapy in 64 patients with lymphangioma

    J Pediatr Surg

    (1994)
  • OgitaS et al.

    A case report of sclerosing therapy with OK-432 for cystic hygroma in a child

    Geka (Surgery)

    (1987)
  • IshidaN et al.
  • OgitaS et al.

    Intracystic injection of OK-432; A new sclerosing therapy for cystic hygroma in children

    Br J Surg

    (1987)
  • UchidaA et al.

    Intrapleural administration of OK-432 in cancer patients: Activation of NK cells and reduction of suppressor cells

    Int J Cancer

    (1983)
  • YoshieO et al.

    Binding and crosslinking of 125I-labeled recombinant human TNF to cell surface receptors

    J Biochem

    (1986)
  • OkamotoH

    Experimental anticancer studies. Part XXXI. On the streptococcal preparation having potent anticancer activity

    Jpn J Exp Med

    (1966)
  • UchidaA et al.

    Clinical studies on cell-mediated immunity in patients with malignant disease

    Cancer

    (1980)
There are more references available in the full text version of this article.

Cited by (0)

Presented at the 42nd Annual International Congress of the British Association of Paediatric Surgeons, Sheffield, England, July 25–28, 1995.

View full text